BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loperto I, Simonetti A, Nardone A, Triassi M. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. Hum Vaccin Immunother 2019;15:1035-47. [PMID: 30735465 DOI: 10.1080/21645515.2019.1578597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Kohli MA, Maschio M, Cartier S, Mould-quevedo J, Fricke F. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany. Vaccines 2022;10:1386. [DOI: 10.3390/vaccines10091386] [Reference Citation Analysis]
2 Fens T, Boer PT, Puijenbroek EPV, Postma MJ. Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review. Vaccines (Basel) 2021;9:111. [PMID: 33540633 DOI: 10.3390/vaccines9020111] [Reference Citation Analysis]
3 Zhang K, Wu X, Shi Y, Gou X, Huang J. Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis. Hum Vaccin Immunother 2021;17:475-84. [PMID: 32692606 DOI: 10.1080/21645515.2020.1777822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]